Table 3 Dose, duration, and side effects of colistin, and treatment results
Dose in patients without renal failure (mg/kg) | 4.90 ± 0.5 | |
Duration (day) | 19.8 ± 10.3 (4–62) | |
● Favorable outcome | 23.1 ± 10.0 (8–62) | |
● Poor outcome or discontinuation of therapy | 11.8 ± 5.6 (4–22) | |
Side effects (renal function impairment) | 3 (7.3%) | |
Using of sedative or analgesic agents during the colistin treatment | 28 (68.3%) | |
Concomitants nephrotoxic agent use | 34 (82.9%) | |
Common nephrotoxic agents used with colistin | ||
● Glycopeptides | 23 (56.1%) | |
● Aminoglycosides | 14 (34.1%) | |
● Furosemide | 11 (26.8%) | |
● Amphotericin B | 10 (24.4%) | |
● Antiviral agent (acyclovir) | 1 (2.4%) | |
● Radiocontrast | 1 (2.4%) | |
Result of treatment: | ||
● Survey | 29 (70.7%) | |
○ Clinical and microbiological response | 28 | |
○ Discontinuation of treatment due to side effect | 1 | |
● Exitus | 12 (29.3%) | |
○ Infection related death | 6 | |
○ Infection unrelated death | 6 |